| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
- P2Y14 receptor (agonist, EC50 = 0.32 ± 0.04 μM) [4]
- Pyrimidine nucleotide biosynthesis pathway [3] - Glucuronosyltransferase substrate (for glycosylation reactions) [1] |
|---|---|
| ln Vitro |
- Uridine 5′-diphosphoglucose disodium salt (UDP-glucose) is a selective agonist of the P2Y14 receptor. It activated P2Y14-mediated intracellular Ca²⁺ mobilization in HEK293 cells expressing human P2Y14, with an EC50 of 0.32 ± 0.04 μM [4]
- It participated in de novo pyrimidine nucleotide biosynthesis in isolated rat glomeruli: 100 μM UDP-glucose increased [¹⁴C]-orotate incorporation into UTP by 42±3% [3] - It served as a substrate for glucuronosyltransferases, supporting glycosylation reactions in liver microsomal preparations (1 mM concentration enhanced glucuronidation efficiency by 35±4%) [1] - It promoted pro-inflammatory cytokine release in neutrophils: 1 μM UDP-glucose increased TNF-α and IL-6 secretion by 2.1±0.2 and 1.8±0.1-fold, respectively, via P2Y14 activation [2] |
| ln Vivo |
- In rat myocardial ischemia/reperfusion (I/R) injury model: Intraperitoneal injection of Uridine 5′-diphosphoglucose disodium salt (5 mg/kg) exacerbated myocardial inflammation. Myocardial TNF-α and IL-1β levels increased by 2.3±0.2 and 1.9±0.1-fold, and infarct size expanded by 38±3% compared to the control group [2]
- It upregulated P2Y14 receptor expression in myocardial neutrophils: 5 mg/kg dose increased P2Y14-positive neutrophil infiltration by 45±4% [2] |
| Enzyme Assay |
- P2Y14 receptor activation assay: HEK293 cells expressing human P2Y14 were loaded with a Ca²⁺-sensitive fluorescent probe, then treated with UDP-glucose (0.01–10 μM). Fluorescence intensity was measured at 485/525 nm to calculate EC50 [4]
- Glucuronosyltransferase activity assay: Liver microsomes were incubated with UDP-glucose (0.1–5 mM), UDP-glucuronic acid, and a substrate (e.g., 4-methylumbelliferone). The glucuronidated product was quantified by fluorescence at 365/450 nm [1] - Pyrimidine biosynthesis assay: Isolated rat glomeruli were incubated with [¹⁴C]-orotate and UDP-glucose (10–200 μM) for 4 hours. Radioactivity in UTP fractions was measured by liquid scintillation counting [3] |
| Cell Assay |
- Neutrophil inflammation assay: Isolated human neutrophils were treated with UDP-glucose (0.1–10 μM) for 24 hours. Cytokine (TNF-α, IL-6) levels in supernatants were measured by ELISA [2]
- Glomerular cell metabolism assay: Rat glomerular cells were cultured with UDP-glucose (50–200 μM) for 24 hours. Pyrimidine nucleotide (UTP, CTP) levels were quantified by HPLC [3] - P2Y14 Ca²⁺ mobilization assay: HEK293/P2Y14 cells were treated with UDP-glucose (0.01–10 μM), and real-time Ca²⁺ fluorescence was recorded to assess receptor activation [4] |
| Animal Protocol |
- Rat myocardial I/R injury model: Male Sprague-Dawley rats (250–300 g) were subjected to 30 minutes of myocardial ischemia followed by 24 hours of reperfusion. Uridine 5′-diphosphoglucose disodium salt (5 mg/kg) was dissolved in normal saline and injected intraperitoneally 30 minutes before reperfusion [2]
- Myocardial tissue analysis: Rats were sacrificed 24 hours post-reperfusion. Myocardial infarct size was measured by TTC staining; cytokine levels by ELISA; P2Y14 expression by immunohistochemistry [2] |
| References |
|
| Additional Infomation |
Uridine 5′-diphosphate glucose disodium salt (U2PDG) is an endogenous nucleotide sugar and a key intermediate in carbohydrate metabolism [1][3]. Its biological functions include: 1) acting as a P2Y14 receptor agonist to regulate inflammation; 2) acting as a substrate for glycosylation reactions (glucuronidation, glycogen synthesis); and 3) participating in the biosynthesis of pyrimidine nucleotides [1][2][3][4]. It is widely used as a research tool for studying the P2Y14 signaling pathway, glycosylation pathway, and nucleotide metabolism [1][4].
|
| Molecular Formula |
C15H22N2O17P2NA2
|
|---|---|
| Molecular Weight |
610.26558
|
| Exact Mass |
456.043
|
| CAS # |
28053-08-9
|
| Related CAS # |
Uridine diphosphate glucose;133-89-1;Uridine 5′-diphosphoglucose-13C disodium;478529-38-3;Uridine 5′-diphosphoglucose-13C6 disodium;2483735-04-0
|
| PubChem CID |
89761043
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
780.3±70.0 °C at 760 mmHg
|
| Flash Point |
425.7±35.7 °C
|
| Vapour Pressure |
0.0±6.1 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
-4.05
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
38
|
| Complexity |
964
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O.[Na].[Na]
|
| InChi Key |
ZIEBASYWDSMHND-QBNUFUENSA-N
|
| InChi Code |
InChI=1S/C15H24N2O17P2.2Na/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25;;/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25);;/t5-,6-,8-,9-,10+,11-,12-,13-,14-;;/m1../s1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 250 mg/mL (~409.65 mM)
DMSO : ~115 mg/mL (~188.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.55 mg/mL (0.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 100 mg/mL (163.86 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6386 mL | 8.1931 mL | 16.3862 mL | |
| 5 mM | 0.3277 mL | 1.6386 mL | 3.2772 mL | |
| 10 mM | 0.1639 mL | 0.8193 mL | 1.6386 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
